Back to search

Article

Personalized Management for EGFRI-Induced Skin Xerosis and Pruritus in NSCLC: A Randomized Trial of a Targeted Repair Balm versus an Emollient 'Plus' 

2026-04-19

Abstract excerpt

<title>Abstract</title> <p> Purpose Dermatologic toxicities, specifically xerosis and pruritus, frequently complicate epidermal growth factor receptor inhibitor (EGFRI) therapy for non-small cell lung cancer (NSCLC), undermining quality of life and treatment adherence. Comparative evidence guiding topical management is lacking. This trial compared two topical regimens to evaluate a symptom-driven, personalized...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
65fb6617-1b5a-5a97-915b-09af76013060
DOI
10.21203/rs.3.rs-8974225/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Personalized Management for EGFRI-Induced Skin Xerosis and Pruritus in NSCLC: A Randomized Trial of a Targeted Repair Balm versus an Emollient 'Plus'DOI 10.21203/rs.3.rs-8974225/v1
Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study.Semantic proximity
Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity
Synergy of de-walled Ganoderma Lucidum spore powder (GLSP) on targeted therapy in advanced non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutant: protocol for a randomized, double-blind, placebo-controlled study.Semantic proximity
Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity
Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.Semantic proximity
Analysis of Influence Factors of Quality of Life of Lung Cancer Patients with Skin Adverse Drug Reactions Under Targeted TherapySemantic proximity
Efficacy of a Tailored Moisturizer for Reducing Chemotherapy-Induced Skin Dryness in Breast Cancer Patients: A Randomized Controlled TrialSemantic proximity
Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.Semantic proximity
EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function.Semantic proximity
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.Semantic proximity
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.Semantic proximity
Integrated Western and Chinese Medicine Interventions for Atopic Dermatitis: A Systematic Review and Meta-analysisSemantic proximity
Select a neighboring publication to make it the new centre.